Avenue Therapeutics, Inc. (ATXI)
Company Info
| ISIN | US05360L2051 |
|---|---|
| CUSIP | 05360L205 |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | Jun 27, 2017 |
Highlights
| Market Cap | $2.91M |
|---|---|
| EPS (TTM) | $37.48 |
| PE Ratio | 0.05 |
| EBITDA (TTM) | -$8.65M |
| Year Range | $1.70 - $26.47 |
| Target Price | $12.00 |
| Short % | 3.56% |
| Short Ratio | 0.73 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: ATXI vs. CRON
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Avenue Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Avenue Therapeutics, Inc. had a return of -84.43% year-to-date (YTD) and -86.81% in the last 12 months.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | -84.43% | 24.72% |
| 1 month | -10.05% | 2.30% |
| 6 months | -48.21% | 12.31% |
| 1 year | -86.81% | 32.12% |
| 5 years (annualized) | -80.53% | 13.81% |
| 10 years (annualized) | N/A | 11.31% |
Monthly Returns
The table below presents the monthly returns of ATXI, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -8.07% | 2.50% | -2.77% | -54.71% | -31.34% | 1.74% | -20.00% | -9.29% | -1.97% | -3.61% | -84.43% | ||
| 2023 | 18.97% | -19.57% | 4.95% | -18.46% | 14.22% | 7.83% | -10.26% | -26.10% | -8.89% | -66.76% | -9.79% | -24.06% | -86.12% |
| 2022 | -19.47% | -53.51% | 41.66% | -23.22% | -24.26% | -3.82% | -4.79% | -6.08% | 179.07% | -76.29% | -43.93% | -13.43% | -91.48% |
| 2021 | -0.50% | -20.61% | 29.15% | -15.65% | -3.12% | -49.40% | -28.69% | 1.12% | -17.68% | 6.04% | -10.76% | -35.60% | -84.74% |
| 2020 | 1.98% | -9.30% | 0.68% | 6.26% | 20.74% | -6.10% | -5.94% | 9.87% | -2.70% | -71.01% | 7.96% | 75.52% | -38.02% |
| 2019 | 12.78% | -8.87% | -14.41% | 3.79% | 5.48% | 21.15% | -5.56% | 5.88% | -5.40% | -3.86% | 2.97% | 62.71% | 77.78% |
| 2018 | 4.14% | 35.54% | -11.74% | -15.96% | 6.86% | -11.60% | 10.34% | -9.11% | -21.45% | 25.18% | 47.59% | 3.65% | 49.17% |
| 2017 | -3.64% | -15.97% | -12.35% | -5.55% | -3.80% | -21.80% | -12.98% | -56.12% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of ATXI is 8, indicating that it is in the bottom 8% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Avenue Therapeutics, Inc. (ATXI) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Avenue Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Avenue Therapeutics, Inc. was 99.99%, occurring on Nov 14, 2024. The portfolio has not yet recovered.
The current Avenue Therapeutics, Inc. drawdown is 99.99%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.99% | Sep 15, 2020 | 1050 | Nov 14, 2024 | — | — | — |
| -74.55% | Jun 28, 2017 | 325 | Oct 10, 2018 | 304 | Dec 26, 2019 | 629 |
| -43.11% | Feb 11, 2020 | 26 | Mar 18, 2020 | 50 | May 29, 2020 | 76 |
| -18.31% | Jun 1, 2020 | 30 | Jul 13, 2020 | 26 | Aug 18, 2020 | 56 |
| -11.46% | Jan 2, 2020 | 10 | Jan 15, 2020 | 8 | Jan 28, 2020 | 18 |
Volatility
Volatility Chart
The current Avenue Therapeutics, Inc. volatility is 25.18%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of Avenue Therapeutics, Inc. compared to its peers in the Biotechnology industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for ATXI in comparison to other companies of the Biotechnology industry. Currently, ATXI has a PE value of 0.1. This PE value is considered to be low compared to the rest of the industry.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for ATXI in comparison to other companies of the Biotechnology industry. Currently, ATXI has a PEG value of 0.0. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Avenue Therapeutics, Inc..
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |